**Core tip:** Chronic hepatitis C (CHC) is the leading cause of cirrhosis and hepatocellular carcinoma and monitoring of liver fibrosis is essential for the prognosis and treatment of these patients. Liver biopsy, the gold standard for fibrosis determination, is invasive and costly. Therefore, novel reliable non-invasive biomarkers are crucial for CHC management. Angiogenesis is closely related to the pathogenesis of the disease and angiopoietins play a relevant role in this process. Interestingly, this study confirms the valuable association of circulating angiopoitein-1 (Ang1) and angiopoitein-2 (Ang2) levels with CHC progression and reveals the outstanding role of Ang2/Ang1 ratio as potential non-invasive biomarker of cirrhosis.

INTRODUCTION
============

Chronic liver disease (CLD) caused by hepatitis C virus (HCV) is an important public health problem worldwide. Nowadays, the number of patients with HCV-related cirrhosis is increasing and at this stage of the disease serious complications, such as bleeding esophageal varices or hepatocellular carcinoma (HCC) development, can take place\[[@B1]-[@B4]\]. Although the new medication based on direct-acting antivirals (DAAs) is very efficient for chronic hepatitis C (CHC) treatment, the access of numerous patients to these novel therapies is difficult because of their elevated cost. In addition, the silent course of disease often leads to many undiagnosed subjects\[[@B4]-[@B6]\].

An important feature of CHC progression is the persistence of HCV in the liver, which perpetuates the inflammatory response and deregulates other repairing processes, leading to angiogenesis, fibrosis, cirrhosis and HCC. Liver fibrosis is characterized by the replacement of hepatocytes by extracellular matrix (ECM), particularly collagen and several extracellular matrix proteins whose organization in non-soluble complex polymers generates the architectural and functional disorganization of the liver\[[@B7]-[@B10]\]. Simultaneously, chronic liver injury leads to the development of abnormal intrahepatic vasculature in a fundamental attempt to reestablish the metabolic interchange between blood and the injured tissue\[[@B11]-[@B14]\]. Indeed, pathological angiogenesis has been reported in diverse CLD and in the context of different inflammatory, fibrotic, and ischemic conditions as well as in HCC\[[@B13],[@B15]-[@B18]\].

Among the mechanisms that closely modulate the angiogenic process, the Angiopoietins/Tie2 system is considered to play a pivotal role during the late phase of angiogenesis and is responsible for the maturation of newly formed vascular structures\[[@B19]-[@B21]\]. The correct regulation of the tyrosine kinase Tie2 is essential for normal vascular development\[[@B22],[@B23]\]. Angiopoitein-1 (Ang1) and angiopoitein-2 (Ang2) have similar affinity toward Tie2 but their effects are quite different and context dependent\[[@B24]-[@B26]\]. Interestingly, the balance between both angiopoietins is altered in several CLD diseases, with its highest manifestation in HCC\[[@B13],[@B27]\].

The knowledge of the fibrosis stage and progression rate is crucial for prognosis and treatment of CHC patients\[[@B28]\], but it is quite difficult to achieve since liver biopsy, the unique clinically accepted tool to evaluate the advance of the disease, has many drawbacks such as its invasiveness and elevated cost\[[@B29]-[@B31]\]. Therefore, alternative strategies are being actively investigated in order to reduce or avoid the need of liver biopsies for the assessment of liver disease\[[@B32],[@B33]\].

In this regard, the close relationship between liver fibrosis and pathological angiogenesis, together with the observed imbalance of angiopoietins levels in different CLD, pointed us to evaluate the usefulness of these angiogenic factors as non-invasive biomarkers of CHC progression\[[@B34],[@B35]\]. Therefore, this study was designed to assess the levels of Ang-1 and Ang-2 in the serum of CHC patients with or without cirrhosis and to estimate their potential diagnostic value.

MATERIALS AND METHODS
=====================

Patients
--------

The study included 179 serum samples from CHC patients without human immunodeficiency virus (HIV), hepatitis B or other liver diseases who had undergone liver biopsy for clinical purposes and gave written informed consent for their experimental use.

The study protocol was approved by the Clinical Research Ethics Committee of Hospital Universitario de La Princesa and adhered to the rules of the Declaration of Helsinki. The diagnosis of CHC was confirmed by the presence of serum HCV-RNA assayed with the reverse transcription polymerase chain reaction (RT-PCR) method (Amplicor Roche Molecular System, Branchburg, NJ). The genotype of HCV was determined by reverse-hybridization line probe assay (INNO-LiPAHCV; Innogenetics, Zwijndreht, Belgium). Also, immediately prior to liver biopsy, a blood sample was taken from each patient to analyse routine biochemical and clinical parameters using standard methods.

Liver histology
---------------

Liver biopsy tissue was obtained from all patients by percutaneous needle extraction (HepafixH, B. Braun Melsungen AG, Melsungen, Germany) under ecographic control. All liver biopsy specimens were fixed in 5% buffered formalin and embedded in paraffin for routine anatomo-pathological examination. Liver fibrosis was staged as F0 to F4 according to the METAVIR classification system\[[@B36]\]. In order to simplify, 3 patients with F0 were included in the F1 group.

Determination of serum Ang1 and Ang2 levels
-------------------------------------------

Concentrations of Ang1 and Ang2 were measured in serum samples from all patients with CHC obtained on the same day that they had undergone percutaneous liver biopsy. According to the manufacturer's directions, levels of Ang1 and Ang2 in serum were evaluated using human enzyme-linked immunosorbent assay (ELISA) Kits (Quantikine: R&D Systems, Minneapolis, MN). Once the reaction was stopped, the absorbance of each well was determined using a microplate reader (BioRad). Concentrations of Ang1 and Ang2 were obtained from the standard curve. All assays were done by duplicate and the mean concentration was calculated.

Statistical analysis
--------------------

All data were analyzed with SPSS version 16.0 software (SPSS Inc., Chicago, IL, United States) and expressed as median values or in percentages, except for age (median and range). Comparisons of Ang1 and Ang2 serum levels between groups of cirrhotic and non-cirrhotic patients were performed by non-parametric Mann-Whitney *U* test. The association of angiopoietins with liver fibrosis was analyzed by the Spearman correlation test. Two-tailed *P* values below 0.05 were considered statistically significant. Receiver operating characteristics (ROC) curves were applied to evaluate the diagnostic precision of angiopoietins and their ratio (Ang2/Ang1) to identify CHC patients with cirrhosis. In addition, different parameters of clinical relevance, such as sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV), positive and negative likelihood ratio (LR), and accuracy (ACC), at different cut-off values (Youden Index - which corresponds to the maximum sum of sensitivity and specificity, 90% sensitivity or 90% specificity) were also determined. Statistic differences among different cirrhosis indices were calculated by De Long test (version 12.3.0.0, MedCalc, MariaKerke, Belgium).

RESULTS
=======

Patient characteristics
-----------------------

Demographic and clinical characteristics of CHC patients are shown in Table [1](#T1){ref-type="table"}. Compared with non-cirrhotic, patients with cirrhosis had lower levels of platelets and albumin but higher levels of bilirubin and transaminases \[except alkaline phosphatase (ALP)\]. No significant differences were found with regard to cholesterol, age, viral load or gender.

###### 

Baseline characteristics of chronic hepatitis C patients

  **Patients**                       **Cirrhotic (*n* = 31)**   **Non-cirrhotic (*n* = 148)**   ***P* value**
  ---------------------------------- -------------------------- ------------------------------- ---------------
  Sex (M/F)                          23/8                       92/56                           0.20
  Age (yr)                           48 (24-63)                 44 (22-67)                      0.23
  Viral load (× 10^5^ IU/mL)         5.0 (3.5-11.0)             7.1 (1.8-13.0)                  0.68
  HCV genotype, *n* (%)                                                                         \-
  1                                  27 (87.1)                  117 (79.1)                      
  Non-1                              4 (12.9)                   31 (20.9)                       
  Stage of liver fibrosis, *n* (%)                                                              \-
  F1                                 \-                         42 (28.4)                       
  F2                                 \-                         66 (44.6)                       
  F3                                 \-                         40 (27.0)                       
  F4                                 31 (100.0)                 \-                              
  AST (UI/L)                         99.0 (60.0-123.0)          48.0 (33.0-65.0)                \< 0.001
  ALT (UI/L)                         116.0 (87.0-161.0)         74.0 (55.3-111.5)               \< 0.001
  ALP (UI/L)                         116.0 (75.0-220.0)         126.5 (77.5-164.8)              0.39
  GGT (UI/L)                         91.0 (68.0-172.0)          36.0 (23.0-65.8)                \< 0.001
  INR                                1.1 (1.1-1.2)              1.0 (0.9-1.1)                   \< 0.001
  Bilirubin (mg/dL)                  0.9 (0.7-1.1)              0.6 (0.5-0.8)                   \< 0.001
  Platelet count (× 10^9^/L)         141.0 (120.0-167.0)        204.0 (167.0-241.0)             \< 0.001
  Cholesterol total (mg/dL)          163.0 (141.0-180.0)        171.0 (154.3-191.5)             0.06
  Albumin (g/dL)                     4.2 (4.0-4.4)              4.3 (4.2-4.6)                   0.03

Data are shown as number of patients (percentage) or median value (25^th^-75^th^ percentile), except for age (median and range). HCV: Hepatitis C virus; AST: Aspartate transaminase; ALT: Alanine transaminase.

Angiopoietins levels in serum of CHC patients
---------------------------------------------

In order to measure serum concentrations of Ang1 and Ang2 in the peripheral blood of CHC patients ELISA assays were performed. Interestingly, the concentration of Ang1 decreased progressively in relation to the stage of liver fibrosis whereas Ang2 levels showed the opposite tendency (Figure [1](#F1){ref-type="fig"}). Furthermore, the concentration of Ang1 in the serum of cirrhotic patients was significantly lower when compared to the non-cirrhotic groups (*P \<* 0.001); On the contrary, Ang2 serum levels were considerably higher in patients with cirrhosis (*P \<* 0.01, Figure [1](#F1){ref-type="fig"}). Hence, differences among fibrosis stages were more evident for Ang2/Ang1 ratio, which was further able to significantly discriminate F \> 1.

![Distribution serum concentrations of Ang1 (A), Ang2 (B) and Ang2/Ang1 ratio values (C) in chronic hepatitis C patients. Medians are represented by horizontal lines. Statistical significance was tested using Mann-Whitney *U*-test. Ang1: Angiopoietin 1; Ang2: Angiopoietin 2.](WJG-22-9744-g001){#F1}

Consequently, Spearman correlation revealed an important association of circulating levels of angiopoietins with fibrosis stage, in accordance to the results shown above: while Ang1 levels were inversely related, Ang2 and Ang2/Ang1 ratio were directly associated (*P \<* 0.0001, all) as Table [2](#T2){ref-type="table"} shows.

###### 

Association between angiopoietins and liver fibrosis in chronic hepatitis C patients

              ***n***   **Rho spearman coefficient**   ***P* value**
  ----------- --------- ------------------------------ ----------------
  Ang1        179       -0.297                         5.25 × 10^-5^
  Ang2        179       0.402                          2.37 × 10^-9^
  Ang2/Ang1   179       0.474                          2.14 × 10^-11^

Ang1: Angiopoietin 1; Ang2: Angiopoietin 2.

Diagnostic accuracy
-------------------

Subsequently, receiver operating curve analyses were performed to demonstrate the diagnostic validity of each individual angiopoietin or combined as a ratio to classify liver fibrosis in CHC. As shown in Figure [2](#F2){ref-type="fig"}, both angiopoietins had a high power to differentiate patients with F \> 1, F \> 2 or cirrhosis. Indeed, the area under the curve (AUC) of Ang1 was 0.734, with a sensitivity 70.97% and a specificity 73.65% at its optimal cut-off for cirrhosis staging; likewise, Ang2 had an AUC of 0.761 for diagnosing CHC patients with cirrhosis, with a sensitivity 74.19% and a specificity 69.59% at the value corresponding to Youden index. Importantly, Ang2/Ang1 ratio displayed the highest precision in discriminating cirrhotic patients (Figure [2](#F2){ref-type="fig"} and Table [3](#T3){ref-type="table"}) with an AUC of 0.810, a sensitivity of 70.97% and a specificity of 84.46% at the optimal cut-off (10.33). Furthermore, the simultaneous analysis of both angiopoietins as a ratio greatly improves other clinically relevant parameters, such as positive likelihood ratio and accuracy (4.57 and 82.1, respectively). Although other cut-offs were inspected in order to improve sensitivity or specificity to 90% (data not shown), optimal criterion (Youden index) displayed better clinical results (Table [3](#T3){ref-type="table"}).

![The receiver operating characteristic curve analysis on the abilities of Ang1, Ang2 and the Ang-2/Ang-1 ratio to diagnose. Significant fibrosis (F \> 1) (A), advanced fibrosis (F \> 2) (B) and cirrhosis (F \> 3) (C) in patients with chronic hepatitis C. Ang1: Angiopoietin 1; Ang2: Angiopoietin 2.](WJG-22-9744-g002){#F2}

###### 

Accuracy of angiopoietins to discriminate significant fibrosis (F \> 1), advanced fibrosis (F \> 2) and cirrhosis (F \> 3) in chronic hepatitis C patients

               **AUC-ROC (95%CI)**    **Criterion**   **Se**   **95%CI**   **Sp**   **95%CI**   **+LR**   **95% CI**   **-LR**   **95%CI**   **+PV**   **95%CI**   **-PV**   **95%CI**   **Cost**   **ACC**
  ------------ ---------------------- --------------- -------- ----------- -------- ----------- --------- ------------ --------- ----------- --------- ----------- --------- ----------- ---------- ---------
  F \> 1                                                                                                                                                                                            
  Ang1         0.650 (0.575 -0.720)   ≤ 54337.63      60.58%   51.9-68.8   69.05%   52.9-82.4   1.96      1.2-3.1      0.57      0.4-0.8     64.40     52.9-74.7   65.5      55.2-74.8   0.35       65.00%
  Ang2         0.664 (0.589-0.732)    \> 4041.67      49.64%   41.0-58.3   83.33%   68.6-93.0   2.98      1.5-6.0      0.60      0.5-0.7     73.30     60.1-84.1   64.2      55.0-72.7   0.33       67.20%
  Ang2/ Ang1   0.724 (0.652- 0.788)   \> 7.162        57.66%   48.9-66.1   78.57%   63.2-89.7   2.69      1.5-4.9      0.54      0.4-0.7     71.30     59.2-81.5   66.8      57.1-75.5   0.32       68.50%
  F \> 2                                                                                                                                                                                            
  Ang1         0.635 (0.560-0.705)    ≤ 47573.25      49.3%    37.2-61.4   75.93%   66.7-83.6   2.05      1.4-3.1      0.67      0.5-0.9     41.80     28.7-55.9   81.0      73.0-87.5   0.31       69.00%
  Ang2         0.712 (0.639-0.777)    \> 4256         60.56%   48.3-72.0   76.85%   67.8-84.4   2.62      1.8-3.9      0.51      0.4-0.7     47.90     34.7-61.3   84.7      77.0-90.6   0.27       72.60%
  Ang2/ Ang1   0.740 (0.669-0.802)    \> 9.262        56.34%   44.0-68.1   85.19%   77.1-91.3   3.80      2.3-6.2      0.51      0.4-0.7     57.20     41.7-71.7   84.7      77.5-90.4   0.22       77.70%
  F \> 3                                                                                                                                                                                            
  Ang1         0.734 (0.663-0.797)    ≤ 47573.25      70.97%   52.0-85.8   73.65%   65.8-80.5   2.69      1.9-3.8      0.39      0.2-0.7     37.90     25.9-51.2   91.8      85.3-96.1   0.27       73.20%
  Ang2         0.761 (0.691-0.821)    \> 4256         74.19%   55.4-88.1   69.59%   61.5-76.9   2.44      1.8-3.4      0.37      0.2-0.7     35.60     24.5-48.1   92.2      85.6-96.5   0.30       70.40%
  Ang2/ Ang1   0.810 (0.744- 0.864)   \> 10.33        70.97%   52.0-85.8   84.46%   77.6-89.9   4.57      2.9-7.1      0.34      0.2-0.6     50.90     35.8-65.9   92.8      87.0-96.5   0.18       82.00%

Youden index criterion. AUC-ROC: Area under the curve of receiver operator characteristics; Se: Sensitivity; Sp: Specificity; +LR: Positive Likelihood ratio; -LR: Negative Likelihood ratio; +PV: Positive predictive value; -PV: Negative predictive value; ACC: Accuracy, *n* = 179 chronic hepatitis C; Ang1: Angiopoietin 1; Ang2: Angiopoietin 2.

Finally, the efficacy of Ang2/Ang1 for cirrhosis staging was compared with other previously described non-invasive serum markers \[aspartate aminotransferase to alanine aminotransferase ratio (AAR), aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis index based on the four factors (FIB4), fibrosis index (FI) and fibrosis-cirrhosis index (FCI)\]. As Table [4](#T4){ref-type="table"} shows, angiopoietins ratio performs better than AAR (*P* = 0.01) and similar to the other indices (*P* \> 0.05).

###### 

Comparisons among area under the curve of receiver operator characteristics from angiopoietin-2/angiopoietin-1 ratio and other non-invasive cirrhosis indices

  **Indices**   **AUC-ROC (95%CI)**   **Standard error**   ***P* value**
  ------------- --------------------- -------------------- ---------------
  Cirrhosis                                                
  Ang2/Ang1     0.810 (0.744-0.864)   0.040                \-
  AAR           0.643 (0.568-0.713)   0.050                0.010
  APRI          0.887 (0.831-0.930)   0.025                0.106
  FIB4          0.858 (0.798-0.906)   0.031                0.349
  FI            0.805 (0.737-0.861)   0.047                0.995
  FCI           0.750 (0.677-0.813)   0.053                0.372

Two-sided *P* values by De Long test. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AAR: AST to ALT ratio; APRI: Aspartate aminotransferase-to-platelet ratio index; FIB4: Combination of biochemical values (platelets, ALT, AST) and age; FI: Fibrosis index; FCI: Fibrosis-cirrhosis index; AUC-ROC: Area under the curve of receiver operator characteristics; Ang1: Angiopoietin 1; Ang2: Angiopoietin 2.

DISCUSSION
==========

CHC is a major cause of progressive liver disease, which often leads to cirrhosis and HCC\[[@B37]\]. Monitoring of liver fibrosis is crucial for the clinical management of patients but its precise determination is only possible by histological examination of liver biopsies\[[@B28]\]. Since vascular remodelling has repeatedly been observed during the evolution of diverse CLD\[[@B13],[@B34],[@B35],[@B38]\], the levels of main related factors, such as angiopoietins, might help to evaluate the progression of these diseases. Previous evidences suggested the possible pathogenic role of the Angiopoietins/Tie-2 system on cirrhosis development, thus highlighting its potential to detect the degree of liver injury\[[@B34],[@B35],[@B38]\]. In this regard, some reports described the significant elevation of Ang2 serum levels in patients with liver cirrhosis\[[@B39]\]. Pauta et al\[[@B40]\] also reported higher levels of Ang2 in the systemic and suprahepatic circulation of cirrhotic patients with alcoholic liver disease and established the inverse correlation of Ang1/Ang2 with prognostic models of the disease. Accordingly, our data indicate that circulating levels of angiopoietins in CHC patients are notably related to fibrosis. Moreover, a significant direct association between Ang2/Ang1 ratio and liver cirrhosis has also been observed. These findings concur with those of Vespasiani-Gentilucci et al\[[@B38]\] who reported a close relationship between fibrosis stage and peripheral levels of Ang1 and Ang2. Therefore, all these data highlight the useful role of these angiogenic factors as non-invasive markers of CHC progression. Furthermore, although ROC analysis revealed high accuracy of both, Ang1 and Ang2, (AUC-ROC \> 0.7) to identify cirrhosis, Ang2/Ang1 ratio displayed the highest value of AUC-ROC (0.810) and showed valuable sensitivity and specificity for the diagnosis of cirrhosis.

In addition, it must be pointed out that Ang2/Ang1 ratio displays similar or superior precision than other proposed tests (AAR, APRI, FIB4, FI, and FCI). In spite the initial outstanding performance of recently defined index, enhanced liver fibrosis (ELF), which combines several variables (hyaluronic acid, tissue inhibitor of matrix metalloproteinases-1, and amino-terminal propeptide of type III procollagen\[[@B41]\], the limited sample size of cirrhotic patients in that cohort (*n =* 29) could lead to overestimate its diagnostic potential\[[@B42]\]. Indeed, angiopoietins ratio displays better AUC-ROCs for cirrhosis identification when ELF is analyzed in a larger cohort of patients (0.81 *vs* 0.78). Finally, it must be noted that Ang2/Ang1 is also simplier and cheaper than other costly and undisclosed procedures such as FibroTest\[[@B43],[@B44]\].

Taken together, these findings suggest that Ang2/Ang1 ratio might constitute a useful minimally invasive indicator of cirrhosis in CHC patients, which could notably help clinical decision-making during patient follow-up. However, the application of this novel biomarker in clinical practice might benefit from further validation.

ACKNOWLEDGMENTS
===============

The authors wish to thank Manuel Gómez Gutiérrez, PhD, for editing the manuscript and each of patients who generously consented to participate.

COMMENTS
========

Background
----------

Hepatitis C virus (HCV) infection often progresses to chronic hepatitis C (CHC), one of the leading causes of cirrhosis and hepatocellular carcinoma (HCC). Angiogenesis is closely related to the pathogenesis of chronic liver disease and its progression to HCC.

Research frontiers
------------------

Several biomarkers have been investigated to predict liver cirrhosis in patients with CHC; however, few studies have evaluated the usefulness of angiogenic factors to identify cirrhosis in these patients despite angiogenesis often concurs with liver fibrosis.

Innovations and breakthroughs
-----------------------------

This study shows that the peripheral value of angiopoietin-2 (Ang2)/angiopoitein-1 (Ang1) was significantly associated with liver fibrosis in patients with CHC, highlighting its potential as novel biomarker for the non-invasive diagnosis of liver fibrosis.

Applications
------------

The laudable discriminatory accuracy displayed by Ang2/Ang1 for fibrosis staging might replace other complex and expensive test for monitoring CHC progression.

Terminology
-----------

The unbalance between Ang1 and Ang2 is present in many tumors such as HCC as well as in diverse chronic liver diseases underlining their potential pathogenic role and their impact as targets for therapeutic intervention.

Peer-review
-----------

This is a study regarding the role of Ang2/Ang1 ratio as a non-invasive biomarker of fibrosis in CHC. Overall, the manuscript was well-written and all tables and figures were appropriate. The main findings about Ang2/Ang1 ratio was quite novel. The idea of assessment of Ang2/Ang1 ratio as a noninvasive biomarker in cirrhosis in chronic hepatitis C is quite interesting.

Manuscript source: Invited manuscript

Specialty type: Gastroenterology and hepatology

Country of origin: Spain

Peer-review report classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

Institutional review board statement: This study was reviewed and approved by the clinical research ethics committee of Hospital Universitario de la Princesa.

Informed consent statement: Written informed consent was obtained from all subjects at the time of enrollment or blood sampling.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Data sharing statement: No additional data are available.

Peer-review started: May 30, 2016

First decision: August 8, 2016

Article in press: October 10, 2016

P- Reviewer: Bunchorntavakul C, Kohla MAS, Komolmit P, Lee HC S- Editor: Yu J L- Editor: A E- Editor: Wang CH

[^1]: Author contributions: Hernández-Bartolomé A contributed to acquisition, analysis and interpretation of data, final approval given; López-Rodríguez R contributed to acquisition, analysis and interpretation of data, critical revision of the manuscript, final approval given; Borque MJ contributed to acquisition of data; González-Moreno L, Real-Martínez Y, García-Buey L and Moreno-Otero R contributed to clinical management of patients, critical revision of the manuscript, final approval given; Sanz-Cameno P contributed to conception and design of the study, analysis and interpretation of data, drafting of the manuscript and final approval given.

    Supported by the Ministerio de Ciencia e Innovación (SAF: 2010/21805, partially); CIBERehd (Instituto de Salud Carlos III, Madrid); Fundación Mutua Madrileña (to Moreno-Otero R); and a grant from Asociación Española Contra el Cáncer (AIO 2010, AECC, to Sanz-Cameno P).

    Correspondence to: Paloma Sanz-Cameno, PhD, Liver Unit, Gastroenterology Service, Instituto Investigación Sanitaria Princesa, IIS-IP, 28006 Madrid, Spain. <paloma_march@hotmail.com>

    Telephone: +34-91-5202334 Fax: +34-91-4022299
